Foundation Medicine names CEO
Mr. Cox brings nearly three decades of proven performance in global, strategic, and operational biopharma leadership and expertise to Foundation Medicine. He’s led or contributed to dozens of successful product launches in the U.S. and abroad.
Mr. Cox joins Foundation Medicine from Roche-Genentech, where he’s led one of the largest oncology portfolios in the U.S..
Before joining Genentech, Mr. Cox held global P&L business unit responsibility within UCB BioPharma, with responsibility for developing and commercializing medicines that serve patients across diverse specialty therapy areas.
Prior to UCB BioPharma, Mr. Cox led a large U.S. primary care business unit for Sanofi-Aventis.
His diverse experience includes senior roles in European country general management, U.S. managed care sales leadership, and U.S. marketing with Schering-Plough.
Mr. Cox received a bachelor's degree in business administration in finance from the University of Kentucky, as well as a master’s of business administration from the University of Missouri. ■
LATEST MOVES FROM Massachusetts
- Chiasma re-appoints Roni Mamluk to board
- BayCoast Bank appoints James Wallace as CFO
- Pulmatrix appoints Amit D. Munshi to board
- Syros Pharmaceuticals appoints Srinivas Akkaraju to board
- Merrimack Pharma names Sergio Santillana as CMO
More inside POST